Precision BioSciences to Present In Vivo Gene Therapy and Ex Vivo Cancer Immunotherapy Data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, the ARCUS genome editing company with novel product development programs in gene therapy, cancer immunotherapy and non-GMO food, will give three presentations at the upcoming ASGCT 21st Annual Meeting held in Chicago, Illinois, May 16-19, 2018.
 
Precision's co-founder and CSO, Derek Jantz, will attend the conference along with a group of Precision scientists. He notes, “The Precision team is looking forward to participating in the research dialogue at ASGCT this year. We are particularly eager to share our experiences towards developing an in vivo gene editing solution, including results of extensive NHP testing. We will also present new data from our gene-edited allogeneic T cell platform, including manufacturing results for our lead CAR T program.”
 
Precision BioSciences presentations at ASGCT include:
1.  

Development and Optimization of a PCSK9-Specific Meganuclease That Mediates Long-Term LDL Reduction in Non-Human Primates (#658; follows content of #657).

   

Oral Session Title: Cardiovascular and Pulmonary Diseases

   

Date and Time: Friday, May 18, 2018, 4:00 p.m. - 5:45 p.m. CDT

   

Location: International Ballroom South

     
2.  

Development of a Clinical-Grade Meganuclease for Allogeneic CAR T Cell Production (#784).

   

Poster Session Title: Cell Therapies III

   

Session Date and Time: Friday, May 18, 2018, 5:45 p.m. - 7:45 p.m. CDT

   

Location: Stevens Salon C & D

     
3.  

A P23H RHO-Specific Meganuclease Rescues Photoreceptor Morphology and Function in Mouse Models of Retinitis Pigmentosa (#565).

   

Poster Session Title: Neurologic Diseases II

   

Session Date and Time: Thursday, May 17, 2018, 5:15 p.m. - 7:15 p.m. CDT

   

Location: Stevens Salon C & D

About Precision BioSciences

Precision BioSciences is a biotechnology company dedicated to improving life. Our mission is to cure genetic disease, overcome cancer, and feed the planet through innovative scientific solutions and with a focus on genome editing. ARCUS®, Precision’s unique, therapeutic-grade genome editing system combines the specificity and efficacy required to translate the promise of gene editing into life changing gene therapies, cell therapies, and agricultural products. To learn more about our platform capabilities and pipeline visit www.precisionbiosciences.com.

About The American Society of Gene & Cell Therapy

ASGCT is the primary membership organization for scientists, physicians, professionals, and patient advocates involved in gene and cell therapy. The Society’s mission is to advance knowledge, awareness and education leading to discovery and clinical application of gene and cell therapies to alleviate disease. ASGCT’s vision is to serve as a catalyst to transform medicine by advancing gene and cell therapies to benefit patients and society.

Contacts

Precision BioSciences
Heather King, +1 919-314-5512
heather.king@precisionbiosciences.com

 
 

Source: Precision BioSciences

Back to news